\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes HealthThe European Partnership ERA4Health has launched its eighth Joint Transnational Call, PREVENT-OO, that will fund multidisciplinary research on understanding and preventing overweight and obesity.
Aim of the call:
Focus on mechanisms of their onset and progression, neglected determinants and novel strategies for critical transitional periods in life. Applications must cover only one of the two following topics:
Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on how to apply will be published on FWO's website soon. Deadline for the submission of pre-proposals is 21 January 2026. Questions on available funding by FWO? Contact europe@fwo.be .
More information on the call, its conditions and how to apply can be found on the ERA4Health dedicated webpage. Interested in applying? Join the information webinar on 18 November 2025 here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
